
The study tested whether eliminating copayments for high-value medications among low-income older adults at high cardiovascular risk would improve clinical outcomes. The randomized trial included 4,761 individuals who were followed for a median of 36 months. The rate of the primary outcome was not reduced by copayment elimination. The IRR for non-fatal MI, non-fatal stroke, and cardiovascular death, death and for cardiovascular-related hospitalizations did not differ between groups. However, there was a modest improvement in medication adherence. The study concludes that eliminating copayments did not improve clinical outcomes or reduce healthcare costs, despite improving medication adherence.
Like
Save
Share